2025. Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s714. DOI:https://doi.org/10.25251/rm8etw25.